Cortexyme, Inc.
NASDAQ: CRTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Casey Lynch
- Employees
- 55
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $70.5M
- Website
- https://www.cortexyme.com
Loading CRTX…
Loading profile data…Frequently asked questions about CRTX
What does Cortexyme, Inc. (CRTX) do?
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingip...
Where does CRTX trade?
Cortexyme, Inc. (CRTX) trades on the NASDAQ Global Select.
What sector is CRTX in?
Cortexyme, Inc. (CRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cortexyme, Inc.?
Casey Lynch is the chief executive officer of Cortexyme, Inc. (CRTX).
Where is Cortexyme, Inc. headquartered?
Cortexyme, Inc. is headquartered in United States.
Does CRTX pay a dividend?
Cortexyme, Inc. (CRTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRTX go public?
Cortexyme, Inc. (CRTX) completed its initial public offering in 2019.